Neurocrine Biosciences on Tuesday won the FDA’s approval for a sprinkle capsule formulation of Ingrezza, providing a more convenient route of treatment for Huntington’s disease patients with trouble swallowing.
Cocrystal Pharma, Inc. announces completion of enrollment of 78 subjects who were infected with influenza A in a randomized, double-blind, placebo-controlled Phase 2a human challenge clinical study evaluating the safety, tolerability, antiviral and clinical measurements of its novel, broad-spectrum, oral PB2 inhibitor CC-42344.
CEO Saum Sutaria says the health system is a “new company” following nine hospital sales in the first quarter.
Tenet raises full-year revenue guidance on $2.2B in Q1 profit Read More »
Despite being hit with a 20% sales decline due to a plunge in demand for its COVID-19 products, Pfizer on Wednesday reported $14.88 billion in revenue in the first quarter of 2024 exceeding analyst expectations.
Pfizer Beats Q1 Forecast Despite 20% Revenue Drop, Cuts Four Pipeline Programs Read More »
The Atlanta area is receiving more physical real estate options to foster its burgeoning biotech industry.
Atlanta’s Biotech Scene Prepares for New Heights Read More »
J&J and BMS’ challenges to Medicare drug price negotiations shut down in federal court less than a week after BMS announced it was laying off more than 2,000 employees.
This week’s legal losses by J&J and BMS reinforce the notion that Medicare drug price negotiation is here to stay, and investors continue to favor biologics over small molecules.
Drug Companies, VCs Rethink R&D Strategies as IRA Stands Strong in Court Read More »
Altamira Therapeutics Ltd. today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the Company’s OligoPhore™ platform and siRNA targeting the p65 protein, a component of the NF-κB transcription factor.
GT Medical Technologies, Inc. today announced it has entered into a strategic distribution partnership with Theragenics Corporation® (Theragenics), a global leader in minimally invasive brachytherapy.
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different pharmaceutical products, disputing the accuracy and relevance of their patents.
